Accord BioPharma Inc, the US specialty division of India-based Intas Pharmaceuticals Ltd, announced on Monday that Intas Pharmaceuticals has completed its acquisition of the UDENYCA (pegfilgrastim-cbqv) business from California-based Coherus BioSciences Inc, a commercial-stage biopharmaceutical company.

A biosimilar to Neulasta (pegfilgrastim), UDENYCA expands the company's portfolio of FDA-approved products and accelerates Accord BioPharma's growth in the biosimilar industry. It is available in three administration options -- autoinjector (AI), on-body injector (OBI) and prefilled syringe (PFS) -- to provide flexibility for patients to receive their treatment at home, on-the-go or in the office.

Following the acquisition, Accord BioPharma will continue to make UDENYCA available to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.